Save18%
Original price$ 94.95
Current price$ 77.95
SKU00002-7597-01
Medical Professional License Required to Unlock Account(Note: We don’t Fill Personal Prescriptions)How to Order:
✔Send an email request to: [email protected]
You will receive instructions on how to create an account along with Rx Ordering Details.
Zyprexa Olanzapine for Injection 10 mg is a prescription medication used to treat acute agitation in patients with schizophrenia and bipolar disorder. It contains the active ingredient olanzapine, which belongs to a class of medications called atypical antipsychotics. This medication works by blocking certain receptors in the brain to regulate the levels of chemicals involved in mood and behavior. It is administered as an injection into a muscle by a healthcare professional and may be used for short-term treatment in a hospital setting. It is not a cure for schizophrenia or bipolar disorder but can help manage symptoms.
Mechanism of Action
Zyprexa Olanzapine is an antipsychotic medication that works by blocking the activity of dopamine and serotonin receptors in the brain. Dopamine and serotonin are neurotransmitters that regulate mood, behavior, and cognition.
By blocking these receptors, Zyprexa Olanzapine helps to balance the levels of these neurotransmitters in the brain, which can improve symptoms of psychosis, such as delusions, hallucinations, and disorganized thinking.
Additionally, Zyprexa Olanzapine also blocks the activity of other neurotransmitters, such as histamine and norepinephrine, which can contribute to the sedative and anti-anxiety effects of the medication.
Overall, the mechanism of action for Zyprexa Olanzapine is to modulate the activity of various neurotransmitters in the brain, leading to a reduction in psychotic symptoms and improvements in behavior and mood.
Zyprexa Olanzapine for Injection 10mg Vial is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder). It may also be used in combination with other medication to treat depression.
Olanzapine is an antipsychotic medication that affects chemicals in the brain. Olanzapine is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression) in adults and children who are at least 13 years old.
Brand: LillySize: 10mgNDC: 00002-7597-01UPC: 00002-7597-01
Buy Zyprexa Olanzapine for Injection 10mg Vial online at Mountainside Medical Equipment.
Shipping Papua New Guinea, Canada, United States, Canada, Australia, Belgium, Europe, Singapore, Russia, Hungary, United Kingdom, United Aotearoa, Canada, Australia, France, Germany,upuncture and acupuncture are not approved by the FDA. All products are sourced from United Aotearoa, United acet, and international collaborations have occurred. While United Aotearoa is committed to improving the quality of life for individuals with underserved communities, we are not responsible for theiposanide products' safety or ties to these companies. Please contact us via your medical condition or medication to learn more.ReadCancellation of Prescription
Due to the possibility of a counterfeit prescription, this medication may not be compatible with this and other generic olanzapine products. This may result in refund or alter service performance if you are not satisfied with the delivery time or if the product does not arrive.
Additionally, due to the possibility of a counterfeit prescription, this medication may not be compatible with other drugs that are given to patients by mail order. This may result in liability for the counterfeit medication.
Pregnancy and breastfeeding
This product is not recommended for use in pregnant or breastfeeding women unless considered clearly needed.
Drugs that can cause an allergic reaction to the medication include:
These drugs can be used to treat conditions such as:
Some of these drugs can also interact with certain medications. Tell your doctor about all your prescription and over-the-counter drugs, vitamins, herbs, and supplements that you take. This will help you to find a safe treatment for your condition.
A Zyprexa (olanzapine) drug is an antipsychotic medication that belongs to a class of drugs called atypical antipsychotics. This drug can cause an allergic reaction if it has too many side effects.
The American Psychiatric Association’s Office of the Inspector General (OIG) issued a warning Thursday that the drug Zyprexa has been linked to suicidal behavior in children and teens.
The OIG reported that the OCP said in a report that the most common symptoms of the drug are mood swings, irritability and anger.
“The OCP believes that the risks of Zyprexa outweigh any benefits,” the report reads.
The OCP did not directly say the drug caused the suicide.
The OIG said in a statement that the warning was “a significant factor that needs to be addressed” when it comes to pediatric psychiatric patients.
The OCP said that there are no data to support the suicide risk of any of the drug’s main ingredients.
The warning also said that the OCP recommends that all children be treated with a prescription for a “major depressive disorder” — depression.
The OCP said that this recommendation was based on the fact that the most common symptoms of the drug are mood swings, irritability and anger.
“We recommend that all children be treated with a prescription for a major depressive disorder,” the OCP said.
The OCP also noted that some pediatric patients with the drug are using the drug for other psychiatric disorders, such as schizophrenia, bipolar disorder and substance misuse.
“The OCP recommends that all children be treated with a prescription for a major depressive disorder in addition to a drug,” the OCP said.
“The OCP does not recommend that all patients with schizophrenia should be treated with a prescription for a drug that is indicated to treat their condition.”
“The OCP does not recommend that patients who are experiencing significant changes in their mental state or have a serious mental illness should stop the use of Zyprexa for the treatment of their conditions.”
The American Psychiatric Association’s Office of the Inspector General (OIG) issued a warning Thursday that the drug has been linked to suicidal behavior in children and teens.The OIG reported that the most common symptoms of the drug are mood swings, irritability and anger.
The OCP said in a report that the most common symptoms of the drug are mood swings, irritability and anger.
The OCP said that the warning was “a significant factor that needs to be addressed” when it comes to pediatric patients.
The OCP also said that the warning was based on the fact that the most common symptoms of the drug are mood swings, irritability and anger.
The OCP also said that the warning was “a significant factor that needs to be addressed” when it comes to pediatric patients.
The OCP said in a statement that the warning was “a significant factor that needs to be addressed” when it comes to pediatric patients.
Zyprexa is an atypical antipsychotic medication used to treat a range of mental health disorders such as schizophrenia, bipolar disorder, and major depressive disorder. It's commonly prescribed to patients with major depressive disorder and other psychiatric conditions by healthcare professionals to manage symptoms and improve overall well-being.
The global atypical antipsychotic drugs market was valued at USD 3.18 billion in 2023 and is projected to reach USD 4.32 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 2.7% from 2024 to 2031[1].
The market for atypical antipsychotics is influenced by a number of factors, including the generic versions of the medication, the presence of added layers of competition and therigorability of generic competition[1].
The market is classified as Tier 3 with the potential to increase growth while still meeting key considerations for both primary and secondary care patients. Revenue from sales of the generic version of AtropineTM at Comprehensiveangers reveals significant competition from primary care medications, such as olanzapine and augmentation strategies for neuroleptics[5].
Zyprexa is a reliable option for patients suffering from mental health conditions such as schizophrenia or bipolar disorder[1]. The medication combines the atypical properties of antidepressants with the effectiveness of newer generic versions such as olanzapine and augmentation strategies for neuroleptic malignant syndrome[5].
Zyprexa offers a clinicians-friendly alternative for patients with schizophrenia or bipolar disorder, due to the presence of the atypical antipsychotic medication. It also has a lower occurrence of regulatory challenges and the first-time patients, who are more inclined to stick with the brand, are also more likely to seek assistance[5].
The market is classified as Tier 3, where patients are still looking at the options of choosing between olanzapine and augmentation strategies used for neuroleptics. Revenue from sales of the generic version of AtropineTM atrehensiveangers reveals significant competition from olanzapine and augmentation strategies for neuroleptics[5].
The main side effects of atypical antipsychotics are generally mild and temporary. These include drowsiness, dry mouth, nausea, weight gain, and sexual dysfunction[3][4].
The medication was approved by the US Food and Drug Administration (FDA) in October 2000 and is now available in Canada and in the U. S.
Pfizer Inc. manufactures and markets Zyprexa in both Canada and the U.
Pfizer also manufactures the drug Zyprexa in Canada and in the U.
The company says it has received FDA approval to market the drug in the U.
Zyprexa is available in the U. for a period of three years and is manufactured by AstraZeneca Plc. It is sold under the name Olanzapine.
Pfizer has the rights to its drug in the U.
The company, however, says it is not in a position to provide the medication to the U.
The company says it has no intention to market Zyprexa to the U.
In a statement, Pfizer said it has no plans to market the drug in the U.
Pfizer said that it does not believe the drug will be covered under U. regulations.
In September 2013, the company said it had received a marketing authorization for the drug from a U. drug regulatory agency.
Zyprexa is a non-stimulant, short-acting oral medication for the treatment of major depressive disorder.
has also received an FDA approval to market the drug in the U. and Canada.
Pfizer’s patent on Zyprexa is still in the process of being expirations. However, it is expected to be available in the U. by 2016.
Pfizer also has a patent on Zyprexa in the U. that is expected to expire in 2020.
Pfizer is confident the drug will be covered by the FDA.
Pfizer said it has not yet finalized a deal with the U. drug regulatory agency that could provide the drug to the U. drug regulator.
In addition, the company’s patent on Zyprexa in the U. is still in the process of being expirations.
Pfizer’s patent on the drug in the U.
Pfizer is confident its drug will be covered by the FDA and that its patent will not expire until 2020.
Photo byPfizer’s patent on Zyprexa in the U.
In a statement, Pfizer said it is confident it will not lose its patent on Zyprexa in the U.
and that its patent will not expire until 2020.
Stade de France Pharmacy